Therapeutic potential of cannabinoids for treating atopic dermatitis
Open Access
- 16 August 2025
- journal article
- review article
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 7 (1) , 57
Abstract
This review aims to assess the therapeutic potential of cannabinoids as complementary treatments for atopic dermatitis. Atopic dermatitis (AD) is a skin disease characterized by the loss of skin barrier function that promotes subsequent symptoms such as intense itching, xerosis and inflammation. Several treatments are available, particularly topical approaches, which are crucial for both acute and chronic management of the disease. The main objectives of topical treatments are to promote skin hydration and reduce itching and immune responses, typically through lotions and topical medications such as glucocorticoids. However, the long-term use of glucocorticoids presents certain disadvantages, highlighting the need for new therapeutic options to minimize adverse effects and providing a broader range of choices for both physicians and patients to find the best alternative for each case. Research involving cannabinoids, which can be endogenous, plant-based or synthetic, has intensified in recent years to evaluate the therapeutic potential of these compounds for skin conditions, including AD. Studies suggest that phytocannabinoids such as cannabidiol (CBD) and Δ-9-tetrahydrocannabinol (THC), along with endogenous and synthetic compounds such as palmitoyletanolamide (PEA) and dronabinol, can improve AD symptoms, primarily because of their anti-inflammatory, antipruritic and antioxidant properties. Additionally, some cannabinoids exhibit antimicrobial effects. Despite these promising results, the use of cannabinoids in AD treatment requires further investigation to better understand their efficiency and safety, necessitating high-accuracy clinical and preclinical trials.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (444648/2023-2)
This publication has 123 references indexed in Scilit:
- Itch and pruritus: what are they, and how should itches be classified?Dermatologic Therapy, 2005
- Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skinJournal of Dermatological Science, 2005
- RNA Interference Suggests a Primary Role for Monoacylglycerol Lipase in the Degradation of the Endocannabinoid 2-ArachidonoylglycerolMolecular Pharmacology, 2004
- The endocannabinoid system and its therapeutic exploitationNature Reviews Drug Discovery, 2004
- Mycophenolate mofetil and its mechanisms of actionImmunopharmacology, 2000
- The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)British Journal of Pharmacology, 2000
- Anandamide amidohydrolase reacting with 2‐arachidonoylglycerol, another cannabinoid receptor ligandFEBS Letters, 1998
- Diagnostic criteria for atopic dermatitisThe Lancet, 1996
- Molecular characterization of a peripheral receptor for cannabinoidsNature, 1993
- Characterization of a class of cationic proteins that specifically interact with intermediate filaments.Proceedings of the National Academy of Sciences, 1981